BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 15606335)

  • 1. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine therapy for metastatic renal cell carcinoma.
    Bukowski RM
    Semin Urol Oncol; 2001 May; 19(2):148-54. PubMed ID: 11354535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Debulking nephrectomy in metastatic renal cancer.
    Flanigan RC
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6335S-41S. PubMed ID: 15448027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic renal cell carcinoma.
    Reeves DJ; Liu CY
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance biotherapy with interleukin-2 and interferon for metastatic renal cell cancer.
    Porta C
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):141-52. PubMed ID: 16375651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytokine therapy for metastatic renal cell carcinoma].
    Eto M; Naito S
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy for renal cell cancer in the era of targeted therapy.
    Coppin C
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience.
    O'Brien MF; Rea D; Rogers E; Bredin H; Butler M; Grainger R; McDermott TE; Mullins G; O'Brien A; Twomey A; Thornhill J
    Eur Urol; 2004 May; 45(5):613-8; discussion 619. PubMed ID: 15082204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
    Kirkali Z
    Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
    [No Abstract]   [Full Text] [Related]  

  • 18. Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
    Belldegrun AS; Klatte T; Shuch B; LaRochelle JC; Miller DC; Said JW; Riggs SB; Zomorodian N; Kabbinavar FF; Dekernion JB; Pantuck AJ
    Cancer; 2008 Nov; 113(9):2457-63. PubMed ID: 18823034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronically administered immunotherapy with low-dose IL-2 and IFN-alpha in metastatic renal cell carcinoma: a feasible option for patients with a good prognostic profile.
    Vaglio A; Alberici F; Maggiore U; Buti S; Potenzoni D; Passalacqua R; Buzio C
    Oncology; 2009; 76(1):69-76. PubMed ID: 19047813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Renal cell carcinoma metastatic to the base of tongue: a case report].
    Kyan A; Kato SN
    Hinyokika Kiyo; 2004 Nov; 50(11):791-3. PubMed ID: 15628540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.